您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SB-431542(hydrate)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SB-431542(hydrate)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SB-431542(hydrate)图片
规格:98%
分子量:384.4
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
Inhibitor of receptors ALK4, ALK5, and ALK7
货号:ajcx23460
CAS:N/A
分子式:C22H16N4O3.XH2O
分子量:384.4
溶解度:DMF: 20 mg/ml,DMSO: 20 mg/ml,DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml,Ethanol: 2 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

SB-431542 is a potent and selective inhibitor of the TGF-β1 receptor ALK5 (IC50= 94 nM)1. It is a less potent antagonist of ALK4 (IC50= 140 nM)2and ALK7.3It does not affect the BMP receptors ALK2, ALK3, ALK6, or a panel of other kinases tested.3SB-431542 specifically blocks Smad signaling, reducing gene expression relevant to fibrosis and cancer.3Through its effects on ALK/Smad signaling, SB-431542 suppresses renewal in embryonic and induced pluripotent stem cells and promotes their differentiation.4,5


1.Callahan, J.F., Burgess, J.L., Fornwald, J.A., et al.Identification of novel inhibitors of the transforming growth factor ß1 (TGF-ß1) type 1 receptor (ALK5)Journal of Medicinal Chemistry45(5)999-1001(2002) 2.Laping, N.J., Grygielko, E., Mathur, A., et al.Inhibition of Transforming Growth Factor (TGF)-ß1-Induced Extracellular Matrix with a Novel Inhibitor of the TGF-ß Type I Receptor Kinase Activity: SB-431542Molecular Pharmacology62(1)58-64(2002) 3.Inman, G.J., NicolÁs, F.J., Callahan, J.F., et al.SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7Molecular Pharmacology62(1)65-74(2002) 4.James, D., Levine, A.J., Besser, D., et al.TGFß/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cellsDevelopment1321273-1282(2005) 5.Chambers, S.M., Fasano, C.A., Papapetrou, E.P., et al.Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signalingNature Biotechnology27(3)275-280(2009)